Respiratory eHealth company Adherium (ASX:ADR) has submitted to the US FDA seeking clearance of its updated Hailie sensor with physiological measures for monitoring Asthma and COPD medication use.
Adherium’s Hailie sensor, which is designed for use with AstraZeneca’s Symbicort aerosol inhaler, is the first in a series of devices specifically designed to enable physicians and providers to enhance patient care and clinical workflow by capturing clinical data and supporting patient management.
This updated Hailie range of products will allow access to reimbursement in the US for the remote monitoring of patients.
“This is an important step in the extension of our digital respiratory management ecosystem. This latest development signals the start of Adherium’s next generation of sensors that capture physiological measures” said Geoff Feakes, Adherium’s chief technology officer.
“Clinicians globally have told us of the importance of building on our core adherence capability to extend the range of clinical data we capture and expand our market coverage of inhaled medications for Asthma and COPD.
"Physiological measures were consistently identified as a key data set to improve patient management and importantly, access reimbursement to enable the widest possible patient population to benefit from the technology.
"As part of Adherium’s market expansion we intend to release a further four new sensors with physiological measures over the next 18 months, taking our anticipated Asthma and COPD medication coverage in the US to over 80% by volume and supporting 18 medications.”